Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 2
1(25.0%)
N/A
1(25.0%)
4Total
Phase 3(2)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03423576Not ApplicableCompleted

Effects of a Comprehensive Patient-centered Health Service in Cystic Fibrosis (VEMSE-CF)

Role: lead

NCT01455675Phase 3Completed

Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients

Role: lead

NCT00662714Phase 3Completed

Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis

Role: lead

NCT00506688Phase 2Completed

Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients

Role: lead

NCT00760071Completed

Magnetic Resonance Imaging (MRI) for Early Diagnosis of Cystic Fibrosis (CF)

Role: collaborator

All 5 trials loaded